



Abba Medix Group

Abba Medix Group finalizes engagement with Jacob Securities Inc. and announces clarification of July 10 press release

TORONTO, ONTARIO, July 16, 2015 – Abba Medix Group Inc. (CSE:ABA) (“Abba” or the “Company”), has entered into an advisory services agreement with Jacob Securities Inc. (“JSI”) pursuant to which JSI continues to provide Abba various strategic and advisory services including advice related to maximizing and realizing the value of Abba and its assets, general management and strategic advice related to Abba’s ongoing operations among other services.

In consideration for acting as strategic advisor, JSI was issued 1,000,000 common Company shares at a price of \$0.40 per share, representing the closing price of the Company’s common shares on the Canadian Securities Exchange on July 2, 2015, by way of a debt settlement private placement pursuant to Section 2 of Policy 6 of the Canadian Securities Exchange.

“We’re very excited to be working with Abba Medix,” said Sasha Jacob, JSI CEO, “With the recent Health Canada announcement allowing medical marijuana licensees to provide a larger selection of cannabis products to Canadians we see the medical marijuana market expanding and maturing.” Abba, with the pending acquisitions of RedeCan Pharm and Blow Vapor, along with its own MMPR application, will be in a unique position to service Canadian medical marijuana users quickly and efficiently.

“Jacob Securities has been at the cutting edge of the Canadian Medical Marijuana market since it was first created,” Ray Rasouli, Abba President and CEO, stated. “Jacob brings a wealth of experience as well as a broad range of contacts in the industry. We appreciate the insights and acumen Jacob continues to bring to Abba.”

The Company would also like to clarify various statements from its press release dated July 10, 2015. In that press release, the Company incorrectly referred to Blow Vapor as a subsidiary of Abba Medix Group Inc. As was announced on April

20, 2015, while Abba and Blow Vapor have entered into a memorandum of understanding, as amended, Abba and Blow Vapor have not entered into a definitive purchase agreement with respect to the transaction and Abba has not completed the acquisition of Blow Vapor. No assurance can be given that a definitive purchase agreement will be entered into or that this acquisition will be completed.

Abba Medix Group Inc. remains committed to the completion of the acquisition of Blow Vapor. Abba will issue a press release with respect to the acquisition of Blow Vapor as required by applicable securities laws and the rules of CSE.

About Abba Medix Group

Abba Medix Group Inc. (CSE:ABA) is a purveyor of fine Canadian medical marijuana, accessories, events and news. The Company intends to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully-integrated, Canadian medical marijuana marketplace. Abba's mission is to find and acquire strong marijuana related businesses, product companies, organizational event sponsorships, and research and development opportunities.

Upon completion of its acquisition of RedeCan, Abba will be a licensed medical marijuana grower and sales agent, authorized to supply Canadian patients.

For more information on Abba Medix Group Inc., please visit www.abbamedix.com. For more information on RedeCan, visit <http://redecapharm.ca> and on Blow Vapor, visit www.blowvapor.com.

About Jacob Securities

Jacob Securities is Canada's leading independent investment dealer focused on renewable energy, clean technology and the medical marijuana sector. Based in Toronto, JSI has completed more transactions in the renewable energy and medical marijuana sectors than any other investment dealer in Canada. JSI has participated in transactions valued in excess of \$7 billion for renewable power projects since 2006 and raised over \$70 million for public and private cannabis companies since 2014. For more information please visit www.jacobsecurities.com.

Cautionary Statements Regarding Forward-Looking Information

Certain statements within this press release relating to the Company constitute "forward-looking statements," within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and / or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are "forward-looking statements." Such "forward-looking

statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and / or sales of medical marijuana, quantities of future medical marijuana production, anticipated revenues in connection with such sales, the overall projected size of the market, completion and / or expansion of production facilities, and other information that is based on forecasts of future results, estimates of production not yet determinable, and other key management assumptions. Actual results may differ materially from those expressed or implied by such forward-looking statements and involve risk and uncertainties relating to the Company's historical experience with regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, and other uninsured risks. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For further information please contact:

Ahmad (Ray) Rasouli

Chief Executive Officer

Abba Medix Group Inc.

Tel: (905) 492-9420